Streetbeat News

Revenues

ACIW

Four financial analysts have recently shared their insights on ACI Worldwide (NASDAQ:ACIW), with all maintaining a bullish stance. The average 12-month price target for ACIW has been raised to $39.25, up 4.19% from the previous target. Analysts from Canaccord Genuity and DA Davidson have maintained their 'Buy' ratings, with price targets of $40 and $39, respectively. Jefferies announced a 'Buy' rating with a $38 target. ACI Worldwide, known for its electronic payment software, has shown a revenue growth of 5.48% and a net margin of 25.73%, outperforming industry averages.

Portfolio Pulse from Benzinga Insights

March 15, 2024 | 7:00 pm

EVA

Enviva has received court approval for its Debtor-in-Possession (DIP) financing and has begun the syndication process for this financing. This step is crucial for Enviva's financial restructuring and operational continuity.

Portfolio Pulse from Benzinga Newsdesk

March 15, 2024 | 6:39 pm

CPS

Consumer Portfolio Services reported a Q4 2023 EPS of $0.29, a decrease from $0.59 YoY. However, their revenue increased to $91.978M from $83.020M YoY.

Portfolio Pulse from Benzinga Newsdesk

March 15, 2024 | 6:06 pm

HOOD

Mizuho analyst Dan Dolev has reiterated a Buy rating on Robinhood Markets, Inc. (NASDAQ:HOOD), raising the price forecast from $17 to $20. The upgrade is based on higher trading volumes, an expanding product portfolio, and solid geographic reach. Robinhood reported a growth in total funded customers to 23.6 million, an acceleration in Assets Under Custody (AUC) to ~$120 billion, and the highest trading activity since January 2022. Net deposits for the quarter have already surpassed $7 billion, exceeding the previous high of $4.6 billion. Dolev highlights Robinhood's potential in AI and international expansion, particularly in Asia, and expects FY24 revenues to grow by 11% to $2.078 billion.

Portfolio Pulse from Nabaparna Bhattacharya

March 15, 2024 | 5:29 pm

BMY

The FDA has granted accelerated approval to Bristol Myers Squibb Co.'s Breyanzi for the treatment of relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, marking its second approval for blood cancers therapy. This approval, which is contingent upon further verification in confirmatory trials, follows a previous approval for large B-cell lymphoma. Breyanzi, a one-time infusion therapy, has shown promising results in clinical trials.

Portfolio Pulse from Vandana Singh

March 15, 2024 | 5:05 pm

THO

Analyst evaluations of Thor Industries (NYSE:THO) over the last three months show a mix of opinions, with a recent shift towards a more positive outlook. The average 12-month price target has been raised to $110.5, indicating a 7.28% increase from the previous target. Key analysts from Citigroup, DA Davidson, Baird, and Truist Securities have all raised their price targets, reflecting optimism about the company's future performance. Despite facing revenue challenges with a -5.93% decline over 3 months, Thor Industries boasts strong financial health indicators such as impressive net margin, ROE, and ROA, along with a balanced debt approach.

Portfolio Pulse from Benzinga Insights

March 15, 2024 | 5:00 pm

CARG

Four analysts have recently shared mixed evaluations of CarGurus (NASDAQ:CARG), with a shift towards a more neutral stance in the last 30 days compared to previous months. The average 12-month price target for CARG has been raised to $26.75, indicating an 11.46% increase from the previous target. Analysts from UBS, Needham, and Oppenheimer have adjusted their ratings and price targets, reflecting dynamic market conditions and CarGurus's performance. Despite these optimistic analyst ratings, CarGurus faces economic challenges, including a significant revenue decline of -22.19%, below-average net margin and ROE, and a low market capitalization, suggesting potential difficulties ahead.

Portfolio Pulse from Benzinga Insights

March 15, 2024 | 5:00 pm

FUTU

Analyst evaluations for Futu Holdings (NASDAQ:FUTU) show a mix of bullish to indifferent sentiments with recent ratings including 2 bullish, 1 somewhat bullish, and 1 indifferent. The average 12-month price target is $64.08, reflecting a 9.63% increase from the previous target. Analysts from Citigroup, JP Morgan, UBS, and Morgan Stanley have adjusted their ratings and price targets, indicating a positive outlook on FUTU's performance. The company's financial overview highlights a strong revenue growth of 36.23%, exceptional net margin of 41.18%, and above-average ROE and ROA, positioning it favorably in the financial sector.

Portfolio Pulse from Benzinga Insights

March 15, 2024 | 4:01 pm

SEIC

SEI Investments (NASDAQ:SEIC) has received mixed analyst ratings over the past quarter, with a shift towards a more positive outlook in recent evaluations. Analysts from Oppenheimer and Piper Sandler have raised their price targets, reflecting optimism about the company's performance. The average 12-month price target for SEIC now stands at $71.75, marking a 7.49% increase from the previous target. SEI Investments, known for its investment processing and management services, has shown a positive revenue trend with a 6.19% growth rate as of December 31, 2023, despite facing challenges in net margin and market capitalization.

Portfolio Pulse from Benzinga Insights

March 15, 2024 | 4:01 pm

EXPD

Analysts have provided diverse opinions on Expeditors Intl (NYSE:EXPD) over the last three months, with recent ratings showing a shift towards a more bearish stance. The average 12-month price target for EXPD has increased to $115.6, reflecting a 4.45% rise from the previous target. Despite a challenging quarter with a -33.82% decline in revenue growth, Expeditors Intl maintains strong financial health indicators, including a high net margin and ROE. Analysts' actions and price target adjustments highlight their evolving expectations for the company.

Portfolio Pulse from Benzinga Insights

March 15, 2024 | 4:00 pm